Sarepta's Duchenne Drug Gains New Panel Review Date, Maybe Optimism
This article was originally published in The Pink Sheet Daily
FDA reschedules eteplirsen's advisory committee meeting for April 25.
You may also be interested in...
Witnesses call for political pressure on FDA to approve the Duchenne drug; patients and advocates also urge general approval reciprocity with Europe and incentives for pediatric trials; agency was not invited to testify.
FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.
Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.